202 related articles for article (PubMed ID: 34176769)
1. Live cell imaging of highly activated natural killer cells against human hepatocellular carcinoma in vivo.
Uong TNT; Yoon MS; Lee KH; Hyun H; Nam TK; Min JJ; Nguyen HPQ; Kim SK
Cytotherapy; 2021 Sep; 23(9):799-809. PubMed ID: 34176769
[TBL] [Abstract][Full Text] [Related]
2. Real-Time Tracking of
Uong TNT; Lee KH; Ahn SJ; Kim KW; Min JJ; Hyun H; Yoon MS
Front Immunol; 2018; 9():825. PubMed ID: 29770131
[TBL] [Abstract][Full Text] [Related]
3. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
4. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.
Hosseinzadeh F; Ai J; Ebrahimi-Barough S; Seyhoun I; Hajifathali A; Muhammadnejad S; Hosseinzadeh F; Shadnoush M; Dabiri Oskouei F; Verdi J
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3797-3803. PubMed ID: 31870124
[TBL] [Abstract][Full Text] [Related]
5. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.
Li D; Li N; Zhang YF; Fu H; Feng M; Schneider D; Su L; Wu X; Zhou J; Mackay S; Kramer J; Duan Z; Yang H; Kolluri A; Hummer AM; Torres MB; Zhu H; Hall MD; Luo X; Chen J; Wang Q; Abate-Daga D; Dropulic B; Hewitt SM; Orentas RJ; Greten TF; Ho M
Gastroenterology; 2020 Jun; 158(8):2250-2265.e20. PubMed ID: 32060001
[TBL] [Abstract][Full Text] [Related]
6. Activity of IL-12/15/18 primed natural killer cells against hepatocellular carcinoma.
Zhuang L; Fulton RJ; Rettman P; Sayan AE; Coad J; Al-Shamkhani A; Khakoo SI
Hepatol Int; 2019 Jan; 13(1):75-83. PubMed ID: 30467624
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotype and antitumor activity of cytokine-induced killer cells from patients with hepatocellular carcinoma.
Yang CK; Huang CH; Hu CH; Fang JH; Chen TC; Lin YC; Lin CY
PLoS One; 2023; 18(1):e0280023. PubMed ID: 36598909
[TBL] [Abstract][Full Text] [Related]
8. Enhanced NK cell activation via eEF2K-mediated potentiation of the cGAS-STING pathway in hepatocellular carcinoma.
Xu Y; Sun F; Tian Y; Zeng G; Lei G; Bai Z; Wang Y; Ge X; Wang J; Xiao C; Wang Z; Hu M; Song J; Yang P; Liu R
Int Immunopharmacol; 2024 Mar; 129():111628. PubMed ID: 38320351
[TBL] [Abstract][Full Text] [Related]
9. RAC1
Shi X; Chen W; Yin Y; Cao H; Wang X; Jiang W; Li Q; Li X; Yu Y; Wang X
Cancer Lett; 2024 Jun; 592():216909. PubMed ID: 38679407
[TBL] [Abstract][Full Text] [Related]
10. Expansion and activation of natural killer cells from PBMC for immunotherapy of hepatocellular carcinoma.
Peng BG; Liang LJ; He Q; Huang JF; Lu MD
World J Gastroenterol; 2004 Jul; 10(14):2119-23. PubMed ID: 15237448
[TBL] [Abstract][Full Text] [Related]
11. NK cells are the crucial antitumor mediators when STAT3-mediated immunosuppression is blocked in hepatocellular carcinoma.
Sui Q; Zhang J; Sun X; Zhang C; Han Q; Tian Z
J Immunol; 2014 Aug; 193(4):2016-23. PubMed ID: 25015826
[TBL] [Abstract][Full Text] [Related]
12. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo.
Wang FS; Liu MX; Zhang B; Shi M; Lei ZY; Sun WB; Du QY; Chen JM
World J Gastroenterol; 2002 Jun; 8(3):464-8. PubMed ID: 12046071
[TBL] [Abstract][Full Text] [Related]
14. High Serum Levels of Cholesterol Increase Antitumor Functions of Nature Killer Cells and Reduce Growth of Liver Tumors in Mice.
Qin WH; Yang ZS; Li M; Chen Y; Zhao XF; Qin YY; Song JQ; Wang BB; Yuan B; Cui XL; Shen F; He J; Bi YF; Ning G; Fu J; Wang HY
Gastroenterology; 2020 May; 158(6):1713-1727. PubMed ID: 31972238
[TBL] [Abstract][Full Text] [Related]
15. IL-15 Overcomes Hepatocellular Carcinoma-Induced NK Cell Dysfunction.
Easom NJW; Stegmann KA; Swadling L; Pallett LJ; Burton AR; Odera D; Schmidt N; Huang WC; Fusai G; Davidson B; Maini MK
Front Immunol; 2018; 9():1009. PubMed ID: 29867983
[TBL] [Abstract][Full Text] [Related]
16. Near-infrared imaging of adoptive immune cell therapy in breast cancer model using cell membrane labeling.
Youniss FM; Sundaresan G; Graham LJ; Wang L; Berry CR; Dewkar GK; Jose P; Bear HD; Zweit J
PLoS One; 2014; 9(10):e109162. PubMed ID: 25334026
[TBL] [Abstract][Full Text] [Related]
17. Characterizing hepatocellular carcinoma stem markers and their corresponding susceptibility to NK-cell based immunotherapy.
Chiang J; Chen PC; Pham J; Nguyen CQ; Kaur K; Raman SS; Jewett A
Front Immunol; 2023; 14():1284669. PubMed ID: 37954598
[TBL] [Abstract][Full Text] [Related]
18. iRGD-modified memory-like NK cells exhibit potent responses to hepatocellular carcinoma.
Dong Y; Huang Y; Zhang Z; Chen A; Li L; Tian M; Shen J; Shao J
J Transl Med; 2023 Mar; 21(1):205. PubMed ID: 36932395
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
[TBL] [Abstract][Full Text] [Related]
20. Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma.
Zhang PF; Gao C; Huang XY; Lu JC; Guo XJ; Shi GM; Cai JB; Ke AW
Mol Cancer; 2020 Jun; 19(1):110. PubMed ID: 32593303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
